On August 18, 2020 SYDNEY–(BUSINESS WIRE)–Australian clinical-stage drug development company Noxopharm reported peer-reviewed publication of research showing that in late-stage prostate cancer patients who have exhausted all standard treatment options, a combination of 177Lu-PSMA-617 and Veyonda is both safe and delivered promising efficacy outcomes, among them a median overall survival of 17.1 months (Press release, Noxopharm, AUG 18, 2020, View Source [SID1234563788]). The independent authors noted that the median overall survival in a study conducted in a comparable patient population (exhausted all standard treatment options; progressive disease) receiving standard chemotherapy was only 4.5 months.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This is excellent news for Noxopharm and adds to the growing evidence that Veyonda has the means to become a standard of care drug in late-stage prostate cancer," said Noxopharm Executive Chairman and CEO Graham Kelly. "177Lu-PSMA-617 therapy is attracting considerable international attention as a promising therapy for men with Stage 4 prostate cancer. It was the subject of a $6 billion series of acquisitions by Novartis in 2018 and we anticipate it becoming a commercially available drug in 2021. We see this publication making a solid case for a combination of Veyonda and 177Lu-PSMA-617 becoming a standard treatment option in late-stage prostate cancer, particularly given that the combination was well-tolerated, even in patients with advanced disease and very limited survival prospects."
The publishing journal, European Urology Oncology, is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer. The publication has been peer-reviewed by a panel of experts in the field. The authors are renowned medical experts from the Kinghorn Cancer Centre, St Vincent’s Hospital Sydney, Garvan Institute of Medical Research, Monash University, Sir Peter MacCallum Department of Oncology (Melbourne University), and Princess Margaret Cancer Centre, Toronto.